Complete regression of a previously untreated melanoma brain metastasis with ipilimumab
- 1 June 2010
- journal article
- case report
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 20 (3), 247-250
- https://doi.org/10.1097/cmr.0b013e3283364a37
Abstract
Anecdotal cases of partial or complete responses have been reported after ipilimumab therapy for stage IV melanoma with brain metastasis treated earlier by surgery or radiosurgery. We report the first case of ipilimumab monotherapy resulting in durable complete remission of untreated, progressive brain metastases in a patient with stage IV melanoma. This case and earlier reports provide support for the further evaluation of ipilimumab in melanoma patients with brain metastasis.Keywords
This publication has 14 references indexed in Scilit:
- Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trialsJournal of Clinical Oncology, 2009
- Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanomaCommunity Oncology, 2008
- Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging studyJournal of Clinical Oncology, 2008
- Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapiesJournal of Clinical Oncology, 2008
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences, 2008
- Immunostimulatory monoclonal antibodies for cancer therapyNature Reviews Cancer, 2007
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapyCurrent Opinion in Immunology, 2006
- Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor MicroenvironmentClinical Cancer Research, 2005
- Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.Proceedings of the National Academy of Sciences, 1996